Merck: signs oncology deal with Japanese drugmakers
(CercleFinance.com) - US drugmaker Merck has signed a strategic collaboration with Japan's Taiho and Astex to discover new cancer treaments, it said in a statement on Monday.
Under the terms of the deal, the companies will combine their preclinical candidates and data from respective research programs.
In exchange for providing Merck an exclusive global license to their small molecule inhibitor candidates, Taiho and Astex will receive an upfront payment of 50 million dollars.
The companies will also be eligible to receive approximately 2.5 billion dollars, depending upon the achievement of preclinical, clinical, regulatory and sales milestones.
Taiho is keeping co-commercialization rights in Japan and an option to promote the druges in specific areas of South East Asia.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Under the terms of the deal, the companies will combine their preclinical candidates and data from respective research programs.
In exchange for providing Merck an exclusive global license to their small molecule inhibitor candidates, Taiho and Astex will receive an upfront payment of 50 million dollars.
The companies will also be eligible to receive approximately 2.5 billion dollars, depending upon the achievement of preclinical, clinical, regulatory and sales milestones.
Taiho is keeping co-commercialization rights in Japan and an option to promote the druges in specific areas of South East Asia.
Copyright (c) 2020 CercleFinance.com. All rights reserved.